BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12853975)

  • 1. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
    Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
    Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
    Bugge TH; Lund LR; Kombrinck KK; Nielsen BS; Holmbäck K; Drew AF; Flick MJ; Witte DP; Danø K; Degen JL
    Oncogene; 1998 Jun; 16(24):3097-104. PubMed ID: 9671388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
    Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
    Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC
    J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
    Whitley BR; Palmieri D; Twerdi CD; Church FC
    Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
    Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
    Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
    Tsuchiya H; Katsuo S; Matsuda E; Sunayama C; Tomita K; Ueda Y; Binder BR
    Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
    Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
    Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
    Maillard CM; Bouquet C; Petitjean MM; Mestdagt M; Frau E; Jost M; Masset AM; Opolon PH; Beermann F; Abitbol MM; Foidart JM; Perricaudet MJ; Noël AC
    Carcinogenesis; 2008 Nov; 29(11):2236-42. PubMed ID: 18753414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
    Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA
    Circ Res; 2004 Sep; 95(6):637-44. PubMed ID: 15297377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.